A randomized pilot trial of oral prednisone taper vs placebo following iv methylprednisolone for multiple sclerosis relapses: Effects on adrenal function and clinical efficacy
- 23 February 2021
- journal article
- letter
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 50, 102867
- https://doi.org/10.1016/j.msard.2021.102867
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysisZeitschrift für Neurologie, 2017
- Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic reviewSeminars in Arthritis and Rheumatism, 2016
- Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trialThe Lancet, 2015
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosisEuropean Journal of Neurology, 2008
- A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbationsMultiple Sclerosis Journal, 2000
- Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance testJournal of Endocrinological Investigation, 1996
- Rating neurologic impairment in multiple sclerosisNeurology, 1983